UB 941
Alternative Names: UB-941Latest Information Update: 21 Dec 2023
At a glance
- Originator Development Center for Biotechnology
- Developer UBI Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein b-raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Thyroid cancer
Most Recent Events
- 20 Dec 2023 Phase-I clinical trials in Cancer in USA and Taiwan (PO) prior to December 2023 (UBI Pharma pipeline, December 2023)
- 20 Dec 2023 Phase-I clinical trials in Colorectal cancer in USA, Taiwan (PO) prior to December 2023 (UBI Pharma pipeline, December 2023)
- 20 Dec 2023 Phase-I clinical trials in Lung cancer in USA, Taiwan (PO) prior to December 2023 (UBI Pharma pipeline, December 2023)